Personal profile
External positions
University of Copenhagen
Fingerprint
Explore the research areas in which Jørn Herrstedt is active. The research areas are based on the researcher's research output in the portal. Combined, the research areas form a unique ‘fingerprint’, which reflects the researcher's professional profile.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Defining and addressing loneliness in older adults with cancer: an international Delphi consensus from the Multinational Association of Supportive Care in Cancer Geriatrics Study Group
Soto-Perez-de-Celis, E., Haase, K. R., Yennu, S., Brain, E., Han, C. Y., Herrstedt, J., Matsuoka, A., Marinho, J., Mustian, L., Pilleron, S., Ramsey, I., Steer, C. & Aapro, M., Jan 2026, In: The Lancet Healthy Longevity. 7, 1, 8 p., 100811.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
Powell, M. A., Cibula, D., O'Malley, D. M., Boere, I., Shahin, M. S., Savarese, A., Chase, D. M., Gilbert, L., Black, D., Herrstedt, J., Sharma, S., Kommoss, S., Gold, M. A., Thijs, A. M., Ring, K., Bolling, M. F., Buscema, J., Gill, S. E., Nowicki, P. & Nevadunsky, N. & 10 others, , Jan 2025, In: Gynecologic Oncology. 192, p. 40-49 10 p.Research output: Contribution to journal › Article › Research › peer-review
-
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
Matulonis, U. A., Herrstedt, J., Oza, A., Mahner, S., Redondo, A., Berton, D., Berek, J. S., Haslund, C. A., Marmé, F., González-Martín, A., Bécourt, S., Tinker, A. V., Ledermann, J. A., Benigno, B., Lindahl, G., Colombo, N., Malinowska, I. A., Liu, W., Bains, M. & Monk, B. J. & 1 others, , Apr 2025, In: Gynecologic Oncology. 195, p. 192-199 8 p.Research output: Contribution to journal › Article › Research › peer-review
-
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel
Chase, D. M., Herrstedt, J., Miller, E. M., Gilbert, L., Zub, O., Mathews, C., Angioli, R., Teneriello, M., Gropp-Meier, M., Powell, M. A., Reyners, A. K. L., Cloven, N. G., Eminowicz, G., Gill, S. E., Maćkowiak-Matejczyk, B., Pothuri, B., Samouëlian, V., Jain, A., Boone, J. & Bouberhan, S. & 10 others, , Aug 2025, In: International Journal of Gynecological Cancer. 35, 8, 9 p., 101935.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Safety and antiemetic efficacy of weekly administration of netupitant/palonosetron plus dexamethasone during 5 weeks of concomitant chemo-radiotherapy-the DANGER-emesis study
Detlefsen, S. S., Andersen, D. S., Knudsen, A. Ø., Nøttrup, T. J., Möller, S., Nyvang, G.-B., Jørgensen, T. L., Herrstedt, J. & Ruhlmann, C. H., 28 May 2025, In: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 33, 6, 10 p., 509.Research output: Contribution to journal › Article › Research › peer-review
Open Access
Prizes
-
Højesteretssagfører Kaj Bunch-Jensen og Allis Bunch-Jensens Legat 2018
Herrstedt, J. (Recipient), 2018
Prize